TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
Webcast to be held tomorrow, April 16, 2021 at 8:30 AM ETNEW YORK, April 15, 2021 (GLOBE NEWSWIRE) — TG…